Alzamend Neuro Statistics
Total Valuation
Alzamend Neuro has a market cap or net worth of $4.81 million. The enterprise value is $4.59 million.
Market Cap | 4.81M |
Enterprise Value | 4.59M |
Important Dates
The last earnings date was Monday, March 25, 2024, after market close.
Earnings Date | Mar 25, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Alzamend Neuro has 6.87 million shares outstanding. The number of shares has increased by 7.62% in one year.
Shares Outstanding | 6.87M |
Shares Change (YoY) | +7.62% |
Shares Change (QoQ) | +7.47% |
Owned by Insiders (%) | 29.64% |
Owned by Institutions (%) | 5.45% |
Float | 4.83M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.16
Current Ratio | 0.16 |
Quick Ratio | n/a |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -1,353.94 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -481.20% |
Return on Capital (ROIC) | n/a |
Revenue Per Employee | n/a |
Profits Per Employee | -$3.10M |
Employee Count | 4 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -91.94% in the last 52 weeks. The beta is 0.02, so Alzamend Neuro's price volatility has been lower than the market average.
Beta (1Y) | 0.02 |
52-Week Price Change | -91.94% |
50-Day Moving Average | 0.92 |
200-Day Moving Average | 2.42 |
Relative Strength Index (RSI) | 35.18 |
Average Volume (30 Days) | 56,896 |
Short Selling Information
The latest short interest is 45,307, so 0.66% of the outstanding shares have been sold short.
Short Interest | 45,307 |
Short Previous Month | 51,223 |
Short % of Shares Out | 0.66% |
Short % of Float | 0.94% |
Short Ratio (days to cover) | 0.47 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -12.39M |
Pretax Income | -12.40M |
Net Income | -12.40M |
EBITDA | -12.35M |
EBIT | -12.39M |
Earnings Per Share (EPS) | -$1.87 |
Balance Sheet
The company has $282,867 in cash and no debt, giving a net cash position of $282,867 or $0.04 per share.
Cash & Cash Equivalents | 282,867 |
Total Debt | n/a |
Net Cash | 282,867 |
Net Cash Per Share | $0.04 |
Equity / Book Value | -4.26M |
Book Value Per Share | -0.62 |
Working Capital | -3.23M |
Cash Flow
In the last 12 months, operating cash flow was -$9.08 million and capital expenditures -$147,243, giving a free cash flow of -$9.23 million.
Operating Cash Flow | -9.08M |
Capital Expenditures | -147,243 |
Free Cash Flow | -9.23M |
FCF Per Share | -$1.31 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Alzamend Neuro does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -7.62% |
Shareholder Yield | -7.62% |
Earnings Yield | -254.66% |
FCF Yield | -189.44% |
Analyst Forecast
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on October 31, 2023. It was a reverse split with a ratio of 1:15.
Last Split Date | Oct 31, 2023 |
Split Type | Reverse |
Split Ratio | 1:15 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |